Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients | NEJM
Original Article from The New England Journal of Medicine — Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Original Article from The New England Journal of Medicine — Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
This mendelian randomization analysis estimates the magnitude of the change in plasma lipoprotein(a) levels needed to have the same evidence of an association with coronary…
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.
The Investor Relations website contains information about Verve Therapeutics’s business for stockholders, potential investors, and financial analysts.
Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would…
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky…
The new Watertown spot offers dosa, biryani, parotta, and many vegetarian-friendly dishes.
Dive into the vibrant world of South Indian flavors!
Stream the latest Ivy League videos on Watch ESPN.
Makary is a close ally of Robert F. Kennedy Jr. and a proponent of his “Make America Healthy Again” movement to fight chronic diseases.